Cystic Fibrosis Weekly Update

Contents:

Real-world Impact of Trikafta Will Be Evaluated in RECOVER Study

Jul 31, 2020 07:00 am | Patricia Inacio, PhD

A new study will assess the real-world effects of Vertex Pharmaceutical‘s Trikafta, a triple combo of elexacaftor, tezacaftor, and ivacaftor approved by the U.S. Food and Drug Administration (FDA) for treating up to 90% of all people with cystic fibrosis (CF). The $3.63 million study (3.06 million euros), called RECOVER, will assess the impact of Trikafta (known as Kaftrio […]
The post Real-world Impact of Trikafta Will Be Evaluated in RECOVER Study appeared first on Cystic Fibrosis News Today.

Thread-based Wearable Device May Help Diagnose, Monitor CF and Other Conditions

Jul 30, 2020 07:00 am | Marta Figueiredo

Researchers have developed the first thread-based flexible patch that can be sewn into clothing to monitor — in real time — several molecules in sweat, including chloride ions, which are dysregulated in cystic fibrosis (CF) patients. The study describing that finding, “Thread-based multiplexed sensor patch for real-time sweat monitoring,” was published recently in the journal Nature NPJ […]
The post Thread-based Wearable Device May Help Diagnose, Monitor CF and Other Conditions appeared first on Cystic Fibrosis News Today.